AVANIR Pharmaceuticals (FRA:AV2B) Total Liabilities : €26.07 Mil (As of Sep. 2014)

View and export this data going back to . Start your Free Trial

What is AVANIR Pharmaceuticals Total Liabilities?

AVANIR Pharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2014 was €26.07 Mil.

AVANIR Pharmaceuticals's quarterly Total Liabilities declined from Mar. 2014 (€40.46 Mil) to Jun. 2014 (€38.07 Mil) and declined from Jun. 2014 (€38.07 Mil) to Sep. 2014 (€26.07 Mil).

AVANIR Pharmaceuticals's annual Total Liabilities increased from Sep. 2012 (€38.16 Mil) to Sep. 2013 (€43.09 Mil) but then declined from Sep. 2013 (€43.09 Mil) to Sep. 2014 (€26.07 Mil).

AVANIR Pharmaceuticals Total Liabilities Historical Data

The historical data trend for AVANIR Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVANIR Pharmaceuticals Total Liabilities Chart

AVANIR Pharmaceuticals Annual Data

Trend

Sep05

Sep06

Sep07

Sep08

Sep09

Sep10

Sep11

Sep12

Sep13

Sep14

Total Liabilities

Get a 7-Day Free Trial

10.79

13.31

38.16

43.09

26.07

AVANIR Pharmaceuticals Quarterly Data
	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14
Total Liabilities	Get a 7-Day Free Trial															43.09	38.20	40.46	38.07	26.07

AVANIR Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

AVANIR Pharmaceuticals's Total Liabilities for the fiscal year that ended in Sep. 2014 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	24.904	+	(0	+	1.165
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	26.07

Total Liabilities	=	Total Assets (A: Sep. 2014 )	-	Total Equity (A: Sep. 2014 )
	=	238.219	-	212.15
	=	26.07

AVANIR Pharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2014 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	24.904	+	(0	+	1.165
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	26.07

Total Liabilities	=	Total Assets (Q: Sep. 2014 )	-	Total Equity (Q: Sep. 2014 )
	=	238.219	-	212.15
	=	26.07

AVANIR Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of AVANIR Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

AVANIR Pharmaceuticals (FRA:AV2B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AVANIR Pharmaceuticals (FRA:AV2B) » Definitions » Total Liabilities

Traded in Other Exchanges

N/A

Address

Website

http://www.avanir.com

Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.

AVANIR Pharmaceuticals (FRA:AV2B) Headlines

No Headlines